Výsledky vyhledávání - "David M Kendall"

Akademický článek

Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families

Autor: Indraneel Banerjee, Julie Raskin, Jean-Baptiste Arnoux, Diva D. De Leon, Stuart A. Weinzimer, Mette Hammer, David M. Kendall, Paul S. Thornton

Publikováno v: Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-12 (2022)

Abstract Background Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in infants and children, and carries a considerable risk of neurological damage and developmental delays if diagnosis and treatment are delayed.

Externí odkaz: https://doaj.org/article/0338a7325f634e74a9ff7f1f063adba0

Zobrazit plný text záznamu

Plný text ve formátu HTML

Results of a 24-Week Trial of Technosphere Insulin Versus Insulin Aspart in Type 2 Diabetes

Autor: David M. Kendall, Byron J. Hoogwerf, Marshall Grant, Marina Basina, Marisa C. Jones, Kevin M. Pantalone

Publikováno v: Endocrine Practice. 27:38-43

Objective To compare glycemic efficacy of Technosphere insulin (TI) versus that of insulin aspart (IA), each added to basal insulin, in type 2 diabetes. Methods This randomized, 24-week trial included subjects aged from 18 to 80 years who were treate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6305cc93231d1f99042834d036517112
https://doi.org/10.1016/j.eprac.2020.11.002

Zobrazit plný text záznamu

Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus

Autor: Byron J. Hoogwerf, Marisa C. Jones, Janet B. McGill, Daniel J. Weiss, Marshall Grant, David M. Kendall

Publikováno v: Journal of Diabetes. 13:164-172

Technosphere Insulin (TI) is an inhaled insulin. Studies comparing TI with short-acting insulin analogues provide important insights on efficacy, dosing, and time course of action.Planned enrollment of 230 subjects was limited to 138 due to premature

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53dbdadcbe9dda0fe6504a12235584d7
https://doi.org/10.1111/1753-0407.13099

Zobrazit plný text záznamu

Comprehensive Pulmonary Safety Review of Inhaled Technosphere® Insulin in Patients with Diabetes Mellitus

Autor: Frank Pompilio, John B. Buse, David M. Kendall, Susanne Steiner, Anne L. Peters, Tiffany S. Tran, Janet B. McGill

Publikováno v: Clinical Drug Investigation

Background and Objective Technosphere® Insulin (TI), a human insulin powder for inhalation (Afrezza®; MannKind Corporation, Westlake Village, CA, USA), is an ultra-rapid-acting inhaled insulin indicated to improve postprandial glycemic control in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145cd8bf0855c7def65a9044996cf4c4
http://europepmc.org/articles/PMC7511468

Zobrazit plný text záznamu

Hypoglycaemia is reduced with use of inhaled Technosphere ® Insulin relative to insulin aspart in type 1 diabetes mellitus

Autor: J. B. Bumpass, Marshall Grant, Janet B. McGill, Simon Heller, Frank Pompilio, David M. Kendall, Elizabeth R. Seaquist, Lawrence Blonde

Publikováno v: Diabetic Medicine. 37:752-759

AIM To evaluate the effect of final HbA1c levels on the incidences of hypoglycaemia in participants with type 1 diabetes treated with inhaled Technosphere® Insulin or subcutaneous insulin aspart, reported in alignment with the International Hypoglyc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::744cd8b1ad3dbd087548c5981a25eef1
https://doi.org/10.1111/dme.14202

Zobrazit plný text záznamu

A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia

Autor: Mette Hammer, Timothy S. Bailey, Jeannett Dimsits, N. Celeste Bailey, David M. Kendall

Publikováno v: Diabetes technologytherapeutics. 24(4)

BACKGROUND Severe hypoglycemic episodes are life-threatening events demanding rapid administration of glucagon by a caregiver or bystander. The glucagon analog dasiglucagon is stable in aqueous formulation and therefore suitable for delivery in a rea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa39ad18b7d85d3d88754fd0517fee0
https://pubmed.ncbi.nlm.nih.gov/34809479

Zobrazit plný text záznamu

137-OR: Dasiglucagon Ready-to-Use Autoinjector Is More Reliably and Quickly Administered than Glucagon Emergency Kit (GEK)

Autor: N. Celeste Bailey, Timothy S. Bailey, Jeannett Dimsits, David M. Kendall, Ramin Tehranchi

Publikováno v: Diabetes. 70

Dasiglucagon is a novel glucagon analog, stable in aqueous solution and suitable for delivery in a ready-to-use autoinjector (HypoPal®) for the treatment of severe hypoglycemia. This study was performed to assess HypoPal device handling vs. GEK duri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0429dd73a29b5501be436ad7b2f2b827
https://doi.org/10.2337/db21-137-or

Zobrazit plný text záznamu

1024-P: Technosphere Insulin Added to Basal Insulin Is Associated with Less Weight Gain than Basal Insulin plus Insulin Aspart or Insulin Analog (Aspart) 70/30 Mixture in Type 2 DM

Autor: David M. Kendall, Jonathan Manoukian, Patrick M. Morey, Byron J. Hoogwerf

Publikováno v: Diabetes. 69

Technosphere Insulin (TI) is a dry-powder formulation of recombinant human insulin adsorbed onto Technosphere microparticles for oral inhalation. Data from two 52-wk randomized phase 3 trials in type 2 DM were combined to analyze the effects of TI on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6706cbeefea0e5726d21ba8cc88478e3
https://doi.org/10.2337/db20-1024-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání